ARAnke Rissmann

Anke Rissmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anke Rissmann has a total of 559 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Case‐malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy

    by Hannah Johnson, Helen Dolk, Maria Loane, Christine Damase‐Michel, Joanne Given, Hedvig Nordeng, Jorieke E. H. Bergman, Iain Carey, Elly Den Hond, Ester Garne, et al.

    Aim: Many women take medications during pregnancy. However, the risk to the fetus from most medications is uncertain. Congenital anomalies are one of the leading causes of infant death and contribute to long‐term disability. Signal detection methods can be used to systematically identify possible medication–anomaly associations that require further investigation. Methods: Data on first trimester medication exposures in pregnancies with a congenital anomaly reported to 14 EUROmediCAT registries with a birth year of 2005–2018 were analysed. Case‐malformed disproportionality analysis identified medication–anomaly signals using a disproportionality signal detection method. Identified signals were then compared to previous EUROmediCAT signal detection studies and ranked based on a proxy for the severity of impact at a population level using the number of estimated excess congenital anomaly cases within the exposed population and the average additional time in hospital over the first year of life. Generalized linear mixed models were used to assess confounding by birth year and registry within the top 20 ranked signals. Results: 1611 medication–outcome pairs with at least three observations were analysed, and 153 signals for 63 different medications were identified. Of the top 20 ranked signals, 10 (involving nine medications) were prioritized for further independent investigation. Conclusion: The signals identified here are hypothesis forming only. Independent studies that adequately account for confounding are subsequently needed to evaluate if the identified signals are causal. Further investigation of signals with low population impact, but high potential individual risk is also recommended.


  • Open Access

    Competencies for medical nutritional counselling of children and adolescents: Analysis of NKLM 2.0 based on an evidence-based catalogue of criteria

    by Lena Sophie Rudolf, Cathleen Bunzel, Lisa-Michelle Dietz, Katja Kröller, Jana Markert, Helen Clara Schörghofer, Mario Meixner, Laura von Iven, Anke Lux, Anke Rissmann

    Breastfeeding and Nutrition Counselling (NC) plays an important role in paediatric and adolescent medicine for the prevention of nutrition-related diseases. The necessary fundamentals should already be taught during undergraduate medical education. The objectives of this paper were 1. to analyse the National Competence-Based Catalogue of Learning Objectives 2.0 (NKLM) with regard to nutrition-related competencies, 2. to identify possible discrepancies, and 3. to formulate recommendations. With the help of a structured literature research, the competency goals which are necessary for primary preventive NC were identified and summarised in a theoretical catalogue of criteria. The NKLM 2.0 was subsequently checked for its content using the qualitative content analysis according to Mayring. The final code system consisted of 82 codes. All 1,426 coded segments were distributed across the code categories as follows: “Preventive nutritional knowledge”: 532 (37.31%), “Communication competencies”: 442 (31%), “NC competencies”: 216 (15.15%), “Nutritional medicine”: 236 (16.55%). No teaching content was identified for 5 codes. Teaching formats and time frames were not specified. NKLM 2.0 covers most of the competencies required for adequate preventive medical NC. There are gaps in nutritional knowledge (nutrition of breastfeeding mothers, cooking and kitchen techniques, eating behaviour) and in nutrition counselling competencies (nudging, sensitive communication about body weight, systemic counselling). These topics can be taught in a targeted manner in communication courses or as part of culinary medicine programs. Mandatory advanced training in paediatrics and adolescent medicine, as well as clear guidelines regarding teaching formats and time requirements, appear to be sensible measures to ensure lasting learning success and effective prevention.

  • Open Access

    51st annual meeting of ICBDSR: data that counts - transforming lives through birth defects surveillance

    by H Malherbe, E Kalk, L. D. Botto, C Mellado, M. A Thomas, A Rissmann

    The 51st Annual Meeting of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) was held from 2 to 5 November 2025 in Magaliesburg, South Africa. The meeting brought together clinicians, epidemiologists, public health practitioners and researchers from 24 countries to discuss advances in the surveillance, prevention, and management of birth defects. Hosting the meeting in South Africa reflected a strategic effort to strengthen engagement with low- and middle-income countries and to expand African participation in global birth defects surveillance initiatives. Scientific sessions addressed methodological developments in surveillance systems, etiological research, and approaches to improving the interpretation and communication of surveillance data for policy and public health action. Emphasis was placed on strengthening data quality, harmonising case definitions and reporting practices across registries, and building technical capacity in emerging surveillance programmes. Contributions from African researchers highlighted both the challenges and opportunities associated with implementing surveillance in resource-constrained settings. The meeting underscored the importance of international collaboration, inclusive surveillance networks, and effective translation of data into prevention strategies and health system planning. Strengthening global surveillance remains essential for informing prevention efforts and improving outcomes for children and families affected by birth defects.

  • Open Access

    The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy

    by Helen Dolk, Christine Damase‐Michel, Joan Morris, Amanda Neville, Ester Garne, Sue Jordan, Anke Rissmann, Alessio Coi, Deirdre Folan, Dieuwke Broekstra, et al.

    Background: The evidence gap relating to the risk of congenital anomalies (CA) associated with first trimester medication exposure in pregnancy is well recognized. Aims: We describe the EUROmediCAT network and databases, and the methodological approach to pregnancy pharmacovigilance. Material and Methods: Multidisciplinary expertise includes CA diagnosis and epidemiology, pharmacoepidemiology, pharmacology and teratology. The EUROmediCAT central database comprises standardized data from 19 EUROCAT CA registries in 14 countries, including more than 40 000 CA cases 1995–2021 with first trimester medication exposure data recorded, and a population coverage of 14.6 million births, growing by more than 650 000 births per year. The distributed database enables federated data analysis across eight countries which can link data from CA registries to electronic healthcare data, with population coverage of up to 900 000 births per year for linkage to maternal prescriptions, of which 300 000 births per year for linkage also to data on all births. Results: The databases have enabled a variety of study designs: case‐malformed control studies, cohort studies, disease cohort studies, signal detection studies, prevalence and ecological studies, and medication utilization studies. Discussion: A key strength is that studies of CA risk can address accurately the specificity of risk by type of CA. Conclusion: EUROmediCAT presents a unique data and expert resource for tackling the enormous evidence gap regarding the safety of medication during pregnancy.


  • Open Access

    Analysis of Prevalence and Mortality Among Neonates and Children With Intestinal Atresia: A Multinational Study, 1974–2015

    by Angie Carreño, Maria Paula Aguilera, Lina Ibañez, Karen Sarmiento, Juan A. Gili, Csaba Siffel, Wendy N. Nembhard, Jorieke E. H. Bergman, Eva Bermejo‐Sánchez, Giovanna Tagliabue, et al.

    Introduction: Small intestinal atresia (SIA) consists of a congenital obstruction of the lumen of the duodenum, jejunum, or ileum with varying severity. The aim of the investigation was to analyze the prevalence and mortality of SIA, using data from the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). Methods: Data on SIA cases were collected from 25 ICBDSR members' surveillance programs in 17 countries over 1974–2015. All pregnancy outcomes were included, but terminations of pregnancy were not available for 11 programs. Statistical analysis is descriptive, and the prevalence is established by the total of SIA cases divided by the total of births. The survival time was calculated, and mortality was analyzed individually using the Kaplan–Meier method for comparison. Results: The total prevalence of SIA was 2.1 per 10,000 births. Iran had the highest prevalence with 11.5 per 10,000 total births (95% CI: 9–14.1); on the other hand, the lowest prevalence of SIA was in Mexico‐Nuevo Leon with 0.5 per 10,000 births (95% CI: 0.3–0.8), and Cali‐Colombia had zero cases. In South America, a higher prevalence of SIA was estimated compared to what was reported in 2000. Most deaths occurred between Day 2 and 6, except in Bogotá‐Colombia, Spain, UK‐Wales, and Mexico, where the deaths occurred on Day 1. The mortality in the first year was 4.3%, but the specific causes of death were not determined in this study. Conclusion: The prevalence of SIA was about 2.1 per 10,000 births during a 41‐year period in 25 centers, with variations in prevalence according to geographical locations. Future research is suggested to analyze changes in trends and the impact of early diagnosis and treatment in mortality.


  • Open Access

    Children With Biliary Atresia Have Substantial Morbidity in Early Childhood and a High Risk of Liver Transplantation

    by Mads Damkjær, Joachim Tan, Maria Loane, Joanne Given, Elisa Ballardini, Clara Cavero‐Carbonell, Mika Gissler, Sue Jordan, Anna Pierini, Anke Rissmann, et al.

    Background: Biliary atresia is a rare but severe congenital anomaly associated with substantial morbidity and mortality in early childhood. Population‐based estimates of survival, surgical management, and liver transplantation across Europe remain limited. This study aimed to describe mortality and morbidity among children born with biliary atresia using multinational population‐based data. Methods: We investigated children diagnosed with biliary atresia across nine registries from five countries within the European surveillance of congenital anomalies network (EUROCAT), covering births from 1995 to 2014. The data were linked to hospital databases and adjusted for regional differences and follow‐up length. Results: Our cohort included 171 children, with an infant mortality rate of 12.3% (95% CI: 7.8–17.6) and a mortality rate before age five of 18.5% (95% CI: 10.7–27.7). Among these children, 151 had undergone surgery, including 133 who received the Kasai procedure by the age of 1 year at a median age of 57 days (95% CI: 51–62 days). By age five, 37% (adjusted percentage, 95% CI: 30–44) had undergone liver transplantation, with the median age at transplantation being 318 days (95% CI: 244–391 days). Median age at death in the first year was over 6 months and was not immediately after surgery. Conclusion: The high mortality and the substantial need for liver transplantation within the first year of life underline the severity of biliary atresia. This highlights the urgent need for further research into pregnancy exposures that may contribute to this rare but severe congenital anomaly to develop primary prevention strategies.

  • Open Access

    Genetic Diagnoses Among Congenital Anomaly Cases in Europe: Data From the EUROCAT Network

    by Jorieke E. H. Bergman, Annie Perraud, Ester Garne, Ingeborg Barisic, David Tucker, Elisa Ballardini, Lea Bruneau, Clara Cavero‐Carbonell, Ianis Cousin, Miriam Gatt, et al.

    Background: Surveillance of congenital anomaly prevalence over time can identify new teratogens. Anomalies with a genetic cause are excluded from the monitoring. Objectives: We examined temporal changes in the proportion of genetic diagnoses among cases with a congenital anomaly. Methods: Data was used from twenty EUROCAT congenital anomaly registries over the birth years 2013 and 2022. All pregnancy outcomes were included. Multilevel binomial regression models were fitted to estimate the annual change in the proportion of genetic diagnoses of all anomalies by registry. Results were additionally reported, excluding cases with trisomy 13, 18, or 21. Results: Overall, 20% of the 100,099 cases in the study had a genetic diagnosis, and this proportion increased annually by 1.4% (95% CI, 0.8%–1.9%); an absolute increase of approximately 3% from 2013 to 2022. After excluding the trisomies, the overall proportion was 10% with an annual increase of 1.2% (95% CI 0.4%–2.0%). There was considerable variation in the proportion of genetic cases per registry. An increasing proportion of genetic diagnoses was found for five congenital anomaly groups, after excluding the trisomies. We hypothesise that the increase in genetic diagnoses is due to increased access to clinical genetic services, more extensive genetic testing, and the identification of new genes as causes of congenital anomalies. Conclusions: The modest increase in genetic diagnoses among cases with a congenital anomaly is not expected to have a large impact on the surveillance of the non‐genetic anomalies in the EUROCAT network. EUROCAT will continue to monitor the proportion of genetic diagnoses every five years.


  • Open Access

    Morbidity in children with major kidney anomalies: a European population-based study

    by Ester Garne, Mads Damkjær, Anke Rissmann, Clara Cavero-Carbonell, Mika Gissler, Amanda Neville, Michele Santoro, Joachim Tan, David Tucker, Maria Loane, et al.

    Knowledge about the prognosis for children born with congenital anomalies is important for counselling parents after a prenatal diagnosis. Nine population-based European Congenital Anomaly registries provided data on all children born 1995–2014 diagnosed with congenital hydronephrosis, multicystic kidney disease (MCKD), or posterior urethral valves (PUV) and on reference children from the same populations. Data up to 2015 on prescriptions, hospital diagnosis, and surgical procedures up to the 10th birthday were obtained by linkage to prescription and hospital databases. The study included 5624 children diagnosed with congenital hydronephrosis, 1314 with MCKD, and 414 with PUV. Children with hydronephrosis or MCKD were 13 times more likely to have prescriptions for antihypertensives compared to reference children before 10 years of age. Around 3% of children with congenital hydronephrosis or MCKD had a diagnosis of kidney failure at the age of 5 years; however, only 1% had a kidney transplantation by the age of 5 years. For children with PUV, 18.3% had a diagnosis of kidney failure and 5% had a kidney transplantation by the age of 5 years. Conclusion: Children born with congenital hydronephrosis and MCKD generally have a low absolute risk of developing kidney failure. Children with PUV have much higher morbidity, with 1 in 5 (18.3%) being diagnosed with kidney failure before the age of 5 years. It is important to monitor these children closely in early childhood in order to prevent or delay kidney failure. What is Known:• Congenital kidney anomalies are a leading cause of pediatric end-stage kidney disease. Children with hydronephrosis, MCKD, and PUV have increased morbidity, but long-term data on medication use and kidney outcomes are limited. What is New:• This population-based study shows a low absolute risk of kidney failure in children born with hydronephrosis or MCKD but a high relative risk. PUV has high morbidity, with 1 in 4 developing kidney failure by age 10. Antibiotic use is high in early childhood, and antihypertensive use increases with age.


  • Open Access

    Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case/non-case malformed study

    by Laura Saint-Lary, Anna-Belle Beau, Agnès Sommet, Valériane Leroy, Maria Loane, Clara Cavero-Carbonell, Ester Garne, Jonathan Hoareau, Anna Latos Bielenska, Isabelle Monier, et al.

    Purpose: Antiretroviral drugs are recommended during pregnancy to achieve HIV viral suppression and reduce mother-to-child transmission. Congenital anomaly signals were reported after fetal exposure to antiretroviral drugs in several studies warranting further investigation. We aimed to evaluate the risk of congenital anomalies after fetal exposure to antiretroviral drugs using the European congenital anomaly registry data. Methods: A case/non-case study was performed, using the EUROmediCAT central database. All the congenital anomalies, exposed to any antiretroviral drugs, were included from 1995 to 2019. We explored each signal identified from the literature for associations between congenital anomalies and specific antiretroviral exposures. We compared antiretroviral exposure between the signal anomalies (cases) and all other malformed registrations (controls). Reporting odds ratio (ROR) and their 95% confidence intervals were estimated and adjusted for registry and maternal age. Results: Between 1995 and 2019, 173 cases of congenital anomalies were observed after any exposure to antiretroviral drugs. The signal previously identified in the literature between congenital heart defects and exposure to zidovudine was confirmed in the main analysis (aROR 3.66 [1.63–8.23]). Other signals identified in the literature were not confirmed, although two cases of hypospadias and two cases of limb defects were reported after zidovudine and atazanavir exposure, respectively. The signal detection analysis did not reveal any new signal after applying the Bonferroni correction. Conclusions: Our study does not reveal new signals but confirms the previously identified signal between congenital heart defects and fetal exposure to zidovudine. The physio-pathological hypothesis induced by zidovudine exposure should be explored in future studies.


  • Risk of Congenital Ocular Anomaly After Prenatal Exposure to Medications: A EUROmediCAT Study

    by E.‐A. Cifuentes, A. Beau, A. Caillet, F. Frémont, A. J. Neville, E. Ballardini, H. Dolk, M. Loane, E. Garne, B. Khoshnood, et al.

    Background: In Europe, the prevalence of congenital ocular anomaly (COA) is estimated at 3.7 per 10,000 births. While certain COAs have a genetic origin, the cause for most patients remains unknown. The role of medications administered during pregnancy in COA genesis in humans is unclear.Objective: To investigate any association between fetal exposure in the first trimester of pregnancy to medications and the occurrence of COA.Methods: We conducted a case‐malformed‐control study using data on 298,351 cases registered as having congenital anomalies (CA) from 19 registries and one healthcare database in 13 European countries. Two analyses were performed: (i) A signal confirmation analysis of signals from the literature, examining associations between COA and specific medications (nitrofurantoin, NSAIDs, opioids, alprazolam, antihypertensives, asthma medications, pyridoxine, and hydroxyethylrutoside). (ii) A signal detection analysis of all medications reported in the database.Results: We identified 4185 COA cases and 232,718 nongenetic and 38,409 genetic controls. We confirmed the association between prenatal opioid exposure and COA (aROR: 2.66, 95% CI: 1.18, 6.02, and 3.22, 95% CI: 1.35, 7.69, for nongenetic and genetic controls, respectively). Signal detection analysis revealed consistent associations for antiglaucoma preparations and miotics (p < 0.01) related to COA. Other associations included congenital cataracts and lens anomalies with desloratadine, congenital glaucoma with antiepileptics, and eyelid malformations with dermatological hydrocortisone.Conclusions: This pharmacoepidemiological study in Europe analyzing COA following fetal medication exposure confirmed reported signals regarding opioids and COA and identified new associations. Validation in independent datasets is necessary to consolidate these findings.